10-K: Neuronetics Reports 2024 Results, Highlights Greenbrook Acquisition Synergies

Neuronetics' 2024 10-K filing reveals a year of strategic shifts, including the acquisition of Greenbrook, aimed at expanding mental health treatment access.

Summary

• Neuronetics' 2024 financial results show a 5% revenue increase to $74.9 million, driven by U.S. revenues of $72.5 million.
• The company reported a net loss of $43.7 million for the year.
• A key strategic move was the acquisition of Greenbrook, effective December 9, 2024, integrating TMS and SPRAVATO therapies.
• Neuronetics estimates an $8.9 billion addressable market for treatment sessions in the U.S.
• The company treated an estimated 195,356 global patients with over 7.1 million treatment sessions through December 31, 2024.
• Neuronetics aims for cash flow break-even in the third quarter of 2025.
• The company is focused on expanding access to Greenbrook's services through targeted awareness programs and referral pathways.
• Neuronetics is pursuing enhancements to the NeuroStar Advanced Therapy System and pipeline development for additional indications.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue increased and a strategic acquisition was completed, the company still faces significant losses and risks. The future outlook is cautiously optimistic.

Positives

• Revenue increased by 5% in 2024.
• The Greenbrook acquisition provides strategic advantages and expands service offerings.
• Neuronetics is a market leader in TMS therapy.
• The company has a large network of clinics and established referral pathways.
• There is growing societal awareness and acceptance of depression as a treatable disease.
• The company has a comprehensive direct sales and support team.
• The company has a large clinical data set supporting the safety and effectiveness of NeuroStar.
• The company has marketing authorizations in the European Union and Japan.

Negatives

• The company reported a net loss of $43.7 million for 2024.
• The company has an accumulated deficit of $419.8 million as of December 31, 2024.
• The company relies on the sale of its NeuroStar Advanced Therapy System and treatment sessions to generate revenues.
• The company operates in a very competitive environment.
• The company relies on single-source suppliers for some components used in our NeuroStar Advanced Therapy System and on a single manufacturer for the assembly of our NeuroStar Advanced Therapy System.
• The company may be unable to achieve or manage its anticipated growth effectively.
• The company faces risks associated with its international business.
• The company may need to raise additional capital to fund its existing commercial operations, develop and commercialize new products and expand its operations.
• The terms of the company's credit facility place restrictions on its operating and financial flexibility and could subject it to potential default.
• The company has had difficulty processing claims.

Risks

• The company may be unable to achieve or sustain profitability in the future.
• If insurance coverage is unavailable or reimbursement from third-party payors for treatments using our products significantly declines, psychiatrists may be reluctant to use our products and our revenues, earnings and cash flows at our Treatment Centers would be substantially reduced.
• The company's revenue has been concentrated among a small number of customers, and if we lose any of these customers and fail to replace them, our revenue may decrease substantially.
• The company's success depends upon patient satisfaction with the effectiveness of our NeuroStar Advanced Therapy System.
• The company operates in a very competitive environment and if we are unable to compete successfully against our existing or potential competitors, our sales and operating results may be negatively affected.
• The loss of certain members of our senior management or our inability to attract and retain highly skilled executives, salespeople, product development, clinicians in our Treatment Centers and other personnel could negatively impact our business.
• The company relies on single-source suppliers for some components used in our NeuroStar Advanced Therapy System and on a single manufacturer for the assembly of our NeuroStar Advanced Therapy System, and we may be unable to find replacements or immediately transition to alternative parties for these components.
• The company relies on a network of third-party distributors to market and distribute our products internationally, and if we are unable to maintain and expand this network, we may be unable to generate anticipated sales.
• If we are not able to obtain and enforce patent protection for our technologies, products, or product candidates, development and commercialization of our products and product candidates may be adversely affected.
• The combination with Greenbrook may fail to realize the anticipated benefits of the Arrangement, and integration efforts have placed significant demands on the Company.
• The Company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.
• Failure to timely or accurately bill for services could have a negative impact on our revenue and cash flow. We have had difficulty processing claims.
• We may be subject to fines, penalties, and other sanctions if we fail to comply with laws governing our business. As a result of the Arrangement, the Company may be subject to additional federal, state and foreign laws.
• Our ability to obtain SPRAVATO from our suppliers on a timely basis at competitive costs could suffer as a result of events that adversely affect our suppliers or cause disruptions in their businesses.
• Our revenue may be negatively impacted if third-party payors impose additional requirements or reduce reimbursement rates.
• There is a concentration of ownership of our common stock by Madryn Asset Management, LP, or Madryn, and Madryn may exert substantial influence over the Company's business, and the interest of Madryn may conflict with those interests of other stockholders.

Future Outlook

Neuronetics aims to maintain and extend its leadership position in TMS therapy and increase the number of patients treated at Treatment Centers, with a goal to achieve cash flow break-even in the third quarter of 2025.

Management Comments

• We believe that mental health is as important as physical health.
• As a global leader in neuroscience, we are delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results.

Industry Context

The announcement reflects a trend towards consolidation in the mental healthcare services market, with companies like Neuronetics seeking to expand their offerings and geographic reach through acquisitions. The focus on TMS and SPRAVATO aligns with the growing interest in non-invasive and alternative treatments for depression.

Comparison to Industry Standards

• Neuronetics competes with other TMS therapy providers such as Brainsway, Magstim, and MagVenture.
• The company also faces competition from pharmaceutical companies developing antidepressant medications.
• Greenbrook faces competition from other physician practice management firms as well as doctors operating their own practices.
• The company believes there is a significant shortage of mental healthcare providers in the United States.

Legal Proceedings

• The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business.
• Medicare Administrative Contractors acting on behalf of CMS, have alleged after a series of audits that we have received approximately $1.2 million in reimbursements that may be subject to recoupment.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Employees may experience changes in benefits and job roles due to the Greenbrook acquisition.
• Customers will have access to a broader range of mental health treatment options.
• Suppliers may see changes in demand and procurement processes.
• Creditors are subject to the terms of the credit facility and the company's ability to meet its obligations.

Next Steps

• Integrate Greenbrook's operations and realize synergies.
• Optimize sales and customer support to accelerate growth.
• Expand access to Greenbrook's services through targeted awareness programs and referral pathways.
• Increase utilization of new and existing active customer sites of NeuroStar Advanced Therapy Systems.
• Pursue enhancements of the NeuroStar Advanced Therapy System and pipeline development for additional indications.

Key Dates

Keywords

Neuronetics, Greenbrook, TMS, SPRAVATO, MDD, Mental Health, NeuroStar, Therapy, Revenue, Acquisition